as of 08-14-2026 2:25pm EST
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.
| Founded: | N/A | Country: | Canada |
| Employees: | N/A | City: | WEST VANCOUVER |
| Market Cap: | N/A | IPO Year: | 2025 |
| Target Price: | N/A | AVG Volume (30 days): | 153.5K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.73 | EPS Growth: | -21344.83 |
| 52 Week Low/High: | $0.06 - $0.52 | Next Earning Date: | N/A |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | -0.02 | Index: | N/A |
| Free Cash Flow: | -28627321.0 | FCF Growth: | N/A |
See how BCTXZ stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "BCTXZ BriaCell Therapeutics Corp. Warrant - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.